Elpiscience is a Shanghai, China and Germantown, MD-based clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy to benefit cancer patients worldwide. This morning Elpiscience announced that its first patient was does in the US Phase I clinical trial of Anti-CD39 monoclonal antibody ES002 for treatment of advanced solid tumors.
Earlier this month, Dr. John Craighead was announced as chief financial officer effective on Jan. 4th 2022. Craighead will lead all finance and corporate development functions for the company.